+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Plasma and cerebrospinal fluid G72 protein levels in schizophrenia and major depressive disorder



Plasma and cerebrospinal fluid G72 protein levels in schizophrenia and major depressive disorder



Psychiatry Research 254: 244-250



G72 is a modulator of D-amino acid oxidase, the enzyme that degrades D-serine, an amino acid that plays a critical role in glutamate neurotransmission, and has been implicated in psychiatric disorders. The aim of this study was to examine whether plasma or cerebrospinal fluid (CSF) G72 protein levels were altered in either schizophrenia or major depressive disorder (MDD) and whether any correlation between G72 levels and disease severity existed. Initially, 27 schizophrenic patients, 26 MDD patients, and 27 healthy controls matched for age, sex, and ethnicity were enrolled. Compared to those of controls, plasma or CSF G72 levels were not significantly different in patients with schizophrenia or MDD. Although we found a significant positive correlation between plasma G72 levels and a positive symptoms score on the positive and negative syndrome scale (PANSS), this was not replicated in the second study (40 schizophrenic patients). CSF G72 levels showed no significant correlation with PANSS scores. In MDD, neither plasma nor CSF G72 levels correlated significantly with depression severity. Since severity of our patients were relatively mild, further investigations in a large number of subjects including drug-free patients, younger patients, and more severely affected patients are warranted.

(PDF emailed within 1 workday: $29.90)

Accession: 060098961

Download citation: RISBibTeXText

PMID: 28477547


Related references

Cerebrospinal fluid BDNF pro-peptide levels in major depressive disorder and schizophrenia. Journal of Psychiatric Research 113: 190-198, 2019

Increased cerebrospinal fluid complement C5 levels in major depressive disorder and schizophrenia. Biochemical and Biophysical Research Communications 497(2): 683-688, 2018

Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. Journal of Psychiatric Research 47(3): 401-406, 2014

Cerebrospinal fluid neural cell adhesion molecule levels and their correlation with clinical variables in patients with schizophrenia, bipolar disorder, and major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry 76: 12-18, 2017

Reduced Serum and Cerebrospinal Fluid Levels of Autotaxin in Major Depressive Disorder. International Journal of Neuropsychopharmacology 22(4): 261-269, 2019

Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder. European Neuropsychopharmacology 17(9): 573-579, 2007

Increased cerebrospinal fluid fibrinogen levels in major depressive disorder replicated in a larger sample set. European Neuropsychopharmacology 26: S403-S404, 2016

Elevated levels of cerebrospinal fluid neuron-specific enolase (NSE), but not S100B in major depressive disorder. World Journal of Biological Psychiatry 16(2): 106-113, 2015

Relationships of Cerebrospinal Fluid Monoamine Metabolite Levels With Clinical Variables in Major Depressive Disorder. Journal of Clinical Psychiatry 78(8): E947-E956, 2017

Major depressive disorder: insight into candidate cerebrospinal fluid protein biomarkers from proteomics studies. Expert Review of Proteomics 14(6): 499-514, 2017

Low cocaine- and amphetamine-regulated transcript (CART) peptide levels in human cerebrospinal fluid of major depressive disorder (MDD) patients. Journal of Affective Disorders 232: 134-138, 2018

Differential melatonin alterations in cerebrospinal fluid and serum of patients with major depressive disorder and bipolar disorder. Comprehensive Psychiatry 68: 34-39, 2017

Cognitive impairment and major depressive disorder in HIV infection and cerebrospinal fluid biomarkers. Arquivos de Neuro-Psiquiatria 71(9b): 689-692, 2014

Hippocampal α7 nicotinic acetylcholine receptor levels in patients with schizophrenia, bipolar disorder, or major depressive disorder. Bipolar Disorders 13(7-8): 701-707, 2012

Identification of differential microRNAs in cerebrospinal fluid and serum of patients with major depressive disorder. Plos One 10(3): E0121975, 2016